These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 11059634

  • 1. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L.
    Blood Press Suppl; 2000; 1():31-5. PubMed ID: 11059634
    [Abstract] [Full Text] [Related]

  • 2. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 3. Improving Prognosis in Hypertension: Exploring the Benefits of Angiotensin II Type 1 Receptor Blockade.
    Ruilope L.
    Blood Press; 2000; 9(sup1):31-35. PubMed ID: 28425803
    [Abstract] [Full Text] [Related]

  • 4. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
    Unger T.
    Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
    [Abstract] [Full Text] [Related]

  • 5. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F.
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [Abstract] [Full Text] [Related]

  • 6. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 7. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 8. Exploring new treatment strategies in heart failure.
    Swedberg K.
    Blood Press Suppl; 2000 Sep; 1():44-8. PubMed ID: 11059637
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 10. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep; 1():40-3. PubMed ID: 11059636
    [Abstract] [Full Text] [Related]

  • 11. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA.
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF.
    J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
    [Abstract] [Full Text] [Related]

  • 14. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [Abstract] [Full Text] [Related]

  • 15. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.
    Brilla CG, Scheer C, Rupp H.
    J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122
    [Abstract] [Full Text] [Related]

  • 16. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
    Sever PS.
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S3-10; discussion S33-4. PubMed ID: 10076915
    [Abstract] [Full Text] [Related]

  • 17. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 18. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 11; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 19. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
    Andersen NH, Knudsen ST, Poulsen PL, Poulsen SH, Helleberg K, Eiskjaer H, Hansen KW, Bek T, Mogensen CE.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun 11; 4(2):96-9. PubMed ID: 12806591
    [Abstract] [Full Text] [Related]

  • 20. AT1 receptor blockade in experimental myocardial ischemia/reperfusion.
    Jalowy A, Schulz R, Heusch G.
    J Am Soc Nephrol; 1999 Jan 11; 10 Suppl 11():S129-36. PubMed ID: 9892153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.